DEFR14A: Biofrontera Inc. Seeks Stockholder Approval for Incentive Plan Amendment at June 12 Meeting

Biofrontera Inc. is asking stockholders to approve an amendment to its 2021 Omnibus Incentive Plan to increase the number of shares available for issuance at the upcoming annual meeting on June 12, 2024.

Summary

• Biofrontera Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024.
• Stockholders will vote on the election of two Class III directors, an amendment to the 2021 Omnibus Incentive Plan, and the ratification of Marcum LLP as the independent registered public accounting firm.
• The key proposal is to amend the 2021 Omnibus Incentive Plan to increase the total number of shares of common stock authorized for issuance from 266,990 to 3,750,000.
• The board of directors recommends voting FOR the election of John J. Borer III, J.D. and Prof. Hermann Luebbert, Ph.D. as Class III directors, FOR the approval of the amendment to the incentive plan, and FOR the ratification of Marcum LLP.
• The record date for determining stockholders eligible to vote is April 15, 2024.
• As of the record date, there were 5,089,413 shares of common stock and 4,806 shares of Series B-1 Convertible Preferred Stock outstanding, representing 5,089,413 and 28,191 votes respectively.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspect comes from the company's effort to secure its future by incentivizing employees, but there are no major positive or negative surprises.

Positives

• The proposed increase in shares available under the 2021 Omnibus Incentive Plan aims to attract, retain, and motivate key personnel by providing long-term, equity-based incentives.
• The board believes the increased share reserve will be adequate through at least 2026.
• The company is using a lower-cost, more environmentally responsible method by distributing proxy materials online.

Risks

• Failure to approve the amendment to the 2021 Omnibus Incentive Plan could limit the company's ability to attract and retain key personnel.
• The classification of the Board of Directors may have the effect of delaying or preventing changes in control of the company.

Future Outlook

The board believes that the increased share reserve under the 2021 Omnibus Incentive Plan will be adequate through at least 2026.

Management Comments

• Prof. Hermann Luebbert, Ph.D., Chief Executive Officer & Chairman, thanked stockholders for their continued support.
• The Board of Directors has determined that combining the roles of Chairman and Chief Executive Officer is the best leadership structure for the Company at this time because of Prof. Luebberts experience with the Companys business and industry, as well as his ability to effectively identify strategic priorities of the Company and facilitate execution of the Companys strategy.

Industry Context

The use of stock-based long-term incentive compensation is a common practice in the pharmaceutical industry to align employee and stockholder interests and to link compensation to company performance.

Comparison to Industry Standards

• Many comparable companies in the biotech and pharmaceutical sectors utilize omnibus incentive plans to attract and retain talent.
• The size of the share reserve requested is within the typical range for companies of Biofrontera's size and stage of development, but the specific details would need to be benchmarked against a peer group for a more precise assessment.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals all maintain similar incentive plans to motivate employees and align their interests with shareholders.

Related Party Transactions

• Biofrontera AG owns more than 5% of Biofrontera Inc.'s common stock, leading to related party transactions.
• The Ameluz License and Supply Agreement (Ameluz LSA) with Biofrontera Pharma involves Biofrontera Inc. purchasing products exclusively from Pharma.
• A Second Amended and Restated License and Supply Agreement (the Second A&R Ameluz LSA) was entered into, effective as of February 13, 2024, by and among the Company, Biofrontera Pharma, and Biofrontera Bioscience.
• The company has a receivable of $2.8 million due from Biofrontera AG for its 50% share of the balance of a legal settlement for which both parties are jointly and severally liable.

Stakeholder Impact

• Approval of the incentive plan amendment could positively impact employees by providing them with equity-based incentives.
• The outcome of the director elections will determine the composition of the board and its oversight of the company.
• Ratification of the auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Incentive Plan, Directors, Biofrontera